TAC4

Chr 17

tachykinin precursor 4

Also known as: EK, HK-1, HK1, PPT-C

TAC4 encodes a tachykinin neurotransmitter that activates tachykinin receptor 1 to regulate blood pressure, immune function, endocrine secretion, pain perception, and smooth muscle contraction through its cleavage products endokinin-A and endokinin-C. Pathogenic variants cause disease through a dominant-negative mechanism, though specific clinical phenotypes associated with TAC4 mutations are not well-established. The gene shows tolerance to loss-of-function variants, suggesting haploinsufficiency is unlikely to be pathogenic.

Summary from RefSeq, UniProt, Mechanism
0
Active trials
2
Pubs (1 yr)
11
P/LP submissions
0%
P/LP missense
1.66
LOEUF
DN
Mechanism· predicted
Clinical SummaryTAC4
Population Constraint (gnomAD)
Low constraint (pLI 0.00) — loss-of-function variants are relatively tolerated in the population.
📋
ClinVar Variants
11 unique Pathogenic / Likely Pathogenic· 9 VUS of 30 total submissions

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint
1.66LOEUF
pLI 0.000
Z-score 0.21
OE 0.92 (0.521.66)
Tolerant

Highly tolerant — LoF variants common in population

Missense Constraint
0.07Z-score
OE missense 0.98 (0.791.21)
58 obs / 59.4 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios
LoF OE0.92 (0.521.66)
00.351.4
Missense OE0.98 (0.791.21)
00.61.4
Synonymous OE1.03
01.21.6
LoF obs/exp: 7 / 7.6Missense obs/exp: 58 / 59.4Syn Z: -0.11
DN
0.75top 25%
GOF
0.7028th %ile
LOF
0.1993th %ile

This gene has evidence for multiple mechanisms of pathogenicity (dominant-negative and gain-of-function). Both the Badonyi & Marsh prediction and the broader genomic evidence point to dominant-negative as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

DNprediction above median
GOFprediction above median

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312.

ClinVar Variant Classifications

30 submitted variants in ClinVar

Classification Summary

Pathogenic10
Likely Pathogenic1
VUS9
Likely Benign1
Benign2
10
Pathogenic
1
Likely Pathogenic
9
VUS
1
Likely Benign
2
Benign

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
0
10
0
10
Likely Pathogenic
0
0
1
0
1
VUS
0
9
0
0
9
Likely Benign
0
1
0
0
1
Benign
1
0
1
0
2
Total11012023

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

TAC4 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →
Clinical Literature
Open Research Assistant →
Key Publications
Landmark & review papers · by relevance
PubMed
Top 3 results · since 2015Search PubMed ↗